Supralimus Stent/Drug Eluting Stent

Additional Details

The outcome of the supralimus is based on the three powerful tools. The ce approved the millennium matrix stent, sirolimus drug and fully biodegradable polymers coating. It has drug sirolimus, which has dual mechanism of action, regulates inflammatory cell function, blocks smooth muscle cell proliferation.

• The unique design and strut locking mechanism offers excellent radial strength and minimum recoil even with thinner strut. • smooth surface, round edges and thin struts of stent minimizes vessel injury and obliging in reduces thrombus formation incidence.

Therapeutic agent-sirolimus:

• A cytostatic drug that has potent immuno suppressive and antiproliferative properties. • inhibits expression of key cytokines necessary for the smooth muscle cell proliferation from the g1 to the s phase of the cell cycle. • as a part of a des system, sirolimus targets the very cause of isr, proliferating vascular smooth muscle cells, arresting their proliferation.